Skip to main content

Advertisement

SpringerLink
Log in

Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Owing to the increasing disparity of organ demand and organ supply the search for optimal immunosuppressive strategies has become a central issue in kidney transplantation (KTX). In the focus today are modifications of the use of calcineurin-inhibitors (CNIs, Cyclosporine A/Tacrolimus) and steroids, as they are nephrotoxic and promote cardiovascular risk factors like arterial hypertension, hyperlipidemia and diabetes mellitus. These modifications can either be withdrawal or avoidance of these substances in combination with new and/or established immunosuppressants. Because about half of all KTXs are performed by or with the help of urologists’ knowledge of modern immunosuppressive regimens is crucial also for urologists. We performed a literature research (PubMed, DIMDI, medline) for CNI- and steroid-sparing protocols and studies to elucidate their influence on graft-function and graft- and patient-survival. New substances and actual studies were also evaluated. Several published reports on CNI- and steroid-sparing protocols after KTX exist, including withdrawal, reduction or avoidance. The time of reduction seems to be crucial: an initially increased immune response should be counterbalanced by an initially intensified immunosuppression. Therefore, late steroid withdrawal seems to be safer than early withdrawal especially in Cyclosporine-based immunosuppression. Steroid avoidance also seems feasible on a CNI based regimen, especially in context with induction therapy. Withdrawal or avoidance of CNIs seems feasible with mycophenolate acid and/or induction therapy with IL 2-receptor antibodies as co-immunosuppressants. This is of interest in grafts with deteriorating function or from donors with extended criteria. Also, CNI- and steroid-free immunosuppression can be successfully performed with new immunosuppressants but results are yet premature. CNI- and/or steroid reduction, withdrawal or even avoidance is feasible. As long-term graft function is the goal of KTX and as more kidneys from donors with extended criteria are transplanted “tailored immunosuppression” will replace standards in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD (2004) Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78:557–565

    Article  PubMed  CAS  Google Scholar 

  2. Kirk AD, Mannon RB, Swanson SJ, Hale DA (2005) Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 18:2–14

    Article  PubMed  CAS  Google Scholar 

  3. Sinclair NR (1992) Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 147:645–657

    PubMed  CAS  Google Scholar 

  4. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D (2000) Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342:605–612

    Article  PubMed  CAS  Google Scholar 

  5. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC (2004) Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 77:769–776

    Article  PubMed  Google Scholar 

  6. Stratta RJ, Armbrust MJ, Oh CS et al (1988) Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 45:323–328

    Article  PubMed  CAS  Google Scholar 

  7. Matas AJ, Ramcharan T, Paraskevas S et al (2001) Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 1:278–283

    Article  PubMed  CAS  Google Scholar 

  8. Ponticelli C, Tarantino A, Montagnino G (2001) Steroid withdrawal in renal transplant recipients. Transplant Proc 33:987–988

    Article  PubMed  CAS  Google Scholar 

  9. Kasiske BL, Chakkera HA, Louis TA, Ma JZ (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910–1917

    PubMed  CAS  Google Scholar 

  10. EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant 17(Suppl 4):1–67

    Google Scholar 

  11. Schulak JA (2004) Steroid immunosuppression in kidney transplantation: a passing era. J Surg Res 117:154–162

    Article  PubMed  Google Scholar 

  12. Opelz G, Dohler B, Laux G (2005) Collaborative transplant study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5:720–728

    Article  PubMed  CAS  Google Scholar 

  13. Borrows R, Chan K, Loucaidou M et al (2006) Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 81:125–128

    Article  PubMed  CAS  Google Scholar 

  14. Loucaidou M, Borrows R, Cairns T et al (2005) Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. Transplant Proc 37:1795–1796

    Article  PubMed  CAS  Google Scholar 

  15. Kramer BK, Kruger B, Mack M et al (2005) Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. Transplant Proc 37:1789–1791

    Article  PubMed  CAS  Google Scholar 

  16. Vanrenterghem Y, van Hooff JP, Squifflet JP et al (2005) Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 5:87–95

    Article  PubMed  CAS  Google Scholar 

  17. Wlodarczyk Z, Walaszewski J, Perner F et al (2005) Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transpl Int 18:157–162

    Article  PubMed  CAS  Google Scholar 

  18. ter Meulen CG, van Riemsdijk I, Hene RJ et al (2004) Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 4(5):803–810

    Article  PubMed  CAS  Google Scholar 

  19. Pascual J, Quereda C, Zamora J, Hernandez D (2005) Spanish group for evidence-based medicine in renal transplantation. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 37:3746–3748

    Article  PubMed  CAS  Google Scholar 

  20. Kim SJ, Lee KW, Lee DS et al (2004) Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. Transplant Proc 36:2098–2100

    Article  PubMed  CAS  Google Scholar 

  21. Calne RY (1987) Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 2:506–507

    Article  PubMed  CAS  Google Scholar 

  22. Tarantino A, Aroldi A, Stucchi L et al (1991) A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 52:53–57

    Article  PubMed  CAS  Google Scholar 

  23. Montagnino G, Tarantino A, Segoloni GP et al (2001) Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation. J Am Soc Nephrol 12:2163–2169

    PubMed  CAS  Google Scholar 

  24. El-Faramawi M, Rohr N, Jespersen B (2006) Steroid-free immunosuppression after renal transplantation—long-term experience from a single centre. Nephrol Dial Transplant (Epub ahead of print)

  25. Birkeland SA (2001) Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 71:1089–1090

    Article  PubMed  CAS  Google Scholar 

  26. Vitko S, Klinger M, Salmela K et al (2005) Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 80:1734–1741

    Article  PubMed  CAS  Google Scholar 

  27. Rostaing L, Cantarovich D, Mourad G et al, CARMEN Study Group (2005) Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79:807–814

    Article  PubMed  CAS  Google Scholar 

  28. Knechtle SJ, Pirsch JD, H Fechner J Jr et al (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3:722–730

    Article  PubMed  CAS  Google Scholar 

  29. Gallagher MP, Hall B, Craig J (2004) A randomized trial of cyclosporine withdrawal in renal-transplantation recipients: 15-year results. Transplantation 78:1653–1660

    Article  PubMed  CAS  Google Scholar 

  30. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al (2003) Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75:1341–1346

    Article  PubMed  CAS  Google Scholar 

  31. Dudley C, Pohanka E, Riad H et al, Mycophenolate Mofetil Creeping Creatinine Study Group (2005) Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” study. Transplantation 79:466–475

    Article  PubMed  CAS  Google Scholar 

  32. Land W, Vincenti F (2005) Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 80:221–234

    Article  Google Scholar 

  33. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T 156 Study Group (2004) Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78:1332–1340

    Article  PubMed  CAS  Google Scholar 

  34. Lorber MI, Mulgaonkar S, Butt KM et al (2005) Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80:244–252

    Article  PubMed  CAS  Google Scholar 

  35. Oberbauer R (2005) Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5:3023

    Article  PubMed  CAS  Google Scholar 

  36. Oberbauer R, Segoloni G, Campistol JM et al (2005) Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18:22–28

    Article  PubMed  CAS  Google Scholar 

  37. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4:1869–1875

    Article  PubMed  CAS  Google Scholar 

  38. Bestard O, Cruzado JM, Gringo JM (2005) Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 37:3729–3732

    Article  PubMed  CAS  Google Scholar 

  39. Zanker B, Schneeberger H, Rothenpieler U et al (1998) Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 66:44–49

    Article  PubMed  CAS  Google Scholar 

  40. Grinyo JM, Cruzado JM, Bestard O (2005) Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 37:3729–3732

    Article  PubMed  Google Scholar 

  41. Vincenti F, Ramos E, Brattstrom C et al (2001) Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71:1282–1287

    Article  PubMed  CAS  Google Scholar 

  42. Groth CG, Backman L, Morales JM et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67:1036–1042

    Article  PubMed  CAS  Google Scholar 

  43. Kreis H, Cisterne JM, Land W et al (2000) Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69:1252–1260

    Article  PubMed  CAS  Google Scholar 

  44. Flechner SM, Goldfarb D, Modlin C et al (2002) Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070–1076

    Article  PubMed  CAS  Google Scholar 

  45. Diekmann F, Gutierrez-Dalmau A, Torregrosa JV, Oppenheimer F, Campistol JM (2005) Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation—a pilot experience. Transplantation 80:1344–1348

    Article  PubMed  CAS  Google Scholar 

  46. Kirk AD, Hale DA, Mannon RB et al (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76:120–129

    Article  PubMed  CAS  Google Scholar 

  47. Vincenti F, Larsen C, Durrbach A et al, Belatacept Study Group (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770–781

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest—disclosure

The authors disclose any commercial relationship such as: consultancies, stock ownership or other equity interests, patents received and/or pending, or any commercial relationship which might be in any way considered related to a submitted article. No institutional affiliations of the authors exist. No funding was granted.

Author information

Authors and Affiliations

  1. Department of Urology, Campus Mitte, Charité University Hospital, Charitéplatz 1, 10117, Berlin, Germany

    Markus Giessing, Tom Florian Fuller & Max Tuellmann

  2. Department of Nephrology, Charité University Hospital, Campus Mitte, Berlin, Germany

    Torsten Slowinski, Klemens Budde & Lutz Liefeldt

Authors
  1. Markus Giessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom Florian Fuller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max Tuellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Torsten Slowinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Klemens Budde
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lutz Liefeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Giessing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giessing, M., Fuller, T.F., Tuellmann, M. et al. Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. World J Urol 25, 325–332 (2007). https://doi.org/10.1007/s00345-007-0157-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0157-8

Keywords

Search

Navigation